Bioassay Expertise Services

About

Bioassay Expertise Services (BES) provides consulting support to organizations throughout the life cycle of their bioanalytical methods. As your consultant, my goal is to expand your organization’s limited resources by addressing all your bioassay requirements (especially the challenging ones!). In addition to traditional, remote consultation services, I offer onsite services in which I operate within your laboratory to assist in building your organization’s internal expertise. My mission is to assist sponsors in getting much-needed therapies into the clinic as safely and quickly as possible while minimizing development costs. In keeping with this mission, BES provides services to non-profit organizations at discounted rates.    

Services

Assay Development Strategy and Design

Detailed assay development plans tailored to your requirements.

Onsite and Remote Support

An extension of your laboratory team to execute bioassay projects. CRO and CDMO analytical management.

Qualification, Validation and Transfer

Analysis of qualification and validation data. Generation of protocols and summary reports. 

Assay Remediation

Troubleshooting and corrective action planning / implementation.

Technical Writing

Everything from drafting test methods to regulatory submissions.

Lab Startup and Training

Experienced guidance to ensure your laboratory’s success from the start.

Bio

Michael Murphy, Ph.D.

I received my Ph.D. in Microbiology and Immunology from Penn State University with an applied focus on the molecular assembly of viruses. In addition to my academic training, I have over 23 years of combined biotech manufacturing and laboratory experience that includes tenures at Wyeth Laboratories (Pfizer), National Cancer Institute – Frederick, Alphavax Human Vaccines, Medicago U.S.A, Jaguar Gene Therapy, and Advanced Medicine Partners. Since 2013, I have led analytical teams, through a “hands on” approach that resulted in the successful development and implementation of numerous assays (including cell-based potency assays) for characterizing virus-like particle (VLP) vaccines, adenovirus-associated viral (AAV) vectors and lentiviral vectors.